Review Suggests Intermittent Fasting Should Be Added to Type 2 Diabetes Treatment Guidelines

A new article published in *The Lancet Diabetes & Endocrinology* advocates for the formal inclusion of intermittent fasting in clinical guidelines for managing type 2 diabetes. Researchers, after reviewing over 225 clinical trials, found that various intermittent fasting styles reduced HbA1c (a key measure of blood sugar control) by 0.3-1.2% in adults with type 2 diabetes. The findings indicate that intermittent fasting is as effective as traditional calorie restriction for blood sugar control and does not increase the risk of dangerous low blood sugar when medications are appropriately adjusted. The authors urge organizations like the American Diabetes Association and the International Diabetes Federation to update their recommendations.

Context

Intermittent fasting has gained popularity as a dietary strategy, with various styles being explored for health benefits. Type 2 diabetes is a chronic condition characterized by insulin resistance and high blood sugar levels, often managed through lifestyle changes and medications. Current guidelines primarily focus on calorie restriction, making this new perspective noteworthy.

Why it matters

The inclusion of intermittent fasting in diabetes treatment guidelines could provide new options for managing type 2 diabetes, a condition affecting millions worldwide. By potentially improving blood sugar control without increasing risks, it may enhance patient outcomes. This approach could also reduce reliance on medications, lowering healthcare costs for patients and systems alike.

Implications

If adopted, the new guidelines could lead to a shift in how type 2 diabetes is managed, potentially benefiting a large patient population. Healthcare providers may need to adjust treatment plans to incorporate intermittent fasting strategies. Additionally, patients may experience improved management of their condition, which could influence their overall health and lifestyle choices.

What to watch

Organizations like the American Diabetes Association and the International Diabetes Federation are expected to review their guidelines in light of this new research. Stakeholders in diabetes care, including healthcare providers and patients, will be monitoring these developments closely. The response from the medical community and subsequent clinical practices will be crucial in the near term.